Genetic Test Developed for Noonan Syndrome
By LabMedica International staff writers Posted on 22 Dec 2010 |
A prenatal diagnostic test was developed to complement clinical diagnosis in cases where there is a suspicion of Noonan Syndrome.
The most frequent gene mutations associated with Noonan Syndrome as well as other genetically related syndromes is examined in this single test and is recommended where there is increased nuchal translucency with normal chromosomes.
A microarray panel for the molecular diagnosis of Noonan and other genetically defective diseases is available. Fifty-two point mutations are examined that are associated with Noonan as well as a differential diagnosis for Costello, Leopard, and Cardiofaciocutaneous syndromes. The syndromes are similar and their phenotypic overlap may be due to the biochemical relationship of the genes mutated in each syndrome to each other. Genes that are mutated in all three of these syndromes encode proteins that function in the mitogen-activated protein (MAP) kinase pathway.
The test was developed by CGC Genetics, (Newark, NJ, USA), who offers a broad menu of over 1,500 molecular diagnostic, cytogenetic and clinical genomic (Clinical Laboratory Improvement Amendments, CLIA) laboratory tests that cover all the major disciplines of medicine.
Noonan Syndrome (NS) is a relatively common autosomal dominant congenital disorder considered a type of dwarfism that affects both males and females equally. It is believed that between approximately 1 in 1,000 and 1 in 2,500 children worldwide are born with NS. It is one of the most common genetic syndromes associated with congenital heart disease, similar in frequency to Down syndrome. However, the range and severity of features can vary greatly in patients with NS. Therefore, the syndrome is not always identified at an early age and this test would lead to prenatal diagnosis.
In most of the families with multiple affected members, NS maps to chromosome 12q24.1. It was reported that approximately half of a group of patients with Noonan syndrome carried a mutation of the PTPN11 gene at that location, which encodes protein tyrosine phosphatase SHP-2.
Related Links:
CGC Genetics
The most frequent gene mutations associated with Noonan Syndrome as well as other genetically related syndromes is examined in this single test and is recommended where there is increased nuchal translucency with normal chromosomes.
A microarray panel for the molecular diagnosis of Noonan and other genetically defective diseases is available. Fifty-two point mutations are examined that are associated with Noonan as well as a differential diagnosis for Costello, Leopard, and Cardiofaciocutaneous syndromes. The syndromes are similar and their phenotypic overlap may be due to the biochemical relationship of the genes mutated in each syndrome to each other. Genes that are mutated in all three of these syndromes encode proteins that function in the mitogen-activated protein (MAP) kinase pathway.
The test was developed by CGC Genetics, (Newark, NJ, USA), who offers a broad menu of over 1,500 molecular diagnostic, cytogenetic and clinical genomic (Clinical Laboratory Improvement Amendments, CLIA) laboratory tests that cover all the major disciplines of medicine.
Noonan Syndrome (NS) is a relatively common autosomal dominant congenital disorder considered a type of dwarfism that affects both males and females equally. It is believed that between approximately 1 in 1,000 and 1 in 2,500 children worldwide are born with NS. It is one of the most common genetic syndromes associated with congenital heart disease, similar in frequency to Down syndrome. However, the range and severity of features can vary greatly in patients with NS. Therefore, the syndrome is not always identified at an early age and this test would lead to prenatal diagnosis.
In most of the families with multiple affected members, NS maps to chromosome 12q24.1. It was reported that approximately half of a group of patients with Noonan syndrome carried a mutation of the PTPN11 gene at that location, which encodes protein tyrosine phosphatase SHP-2.
Related Links:
CGC Genetics
Latest Molecular Diagnostics News
- Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays